In the offering, the Boca Raton, Fla.-based company plans to offer 2.2 million shares of its common stock at a price of $6.80 per share, bringing in approximately $15 million in gross proceeds.
The offering also includes a 30-day underwriter’s option to purchase an additional 330,882 shares for the same price, which could pull in approximately $2.3 million extra for the company, before underwriting discounts and other expenses. The offering is expected to close on September 17.
Sensus said it plans to use net proceeds for general corporate purposes including R&D, expansion of product lines and roll-out of new products, according to a press release.
Last month, Sensus Healthcare said that it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.